TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04074226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane block
Description: The Erector Spinae Plane (ESP) block is a new block first described in 2016 which blocks terminal branches of the lower thoracic and lumbar nerve roots. It is performed by injection of local anesthetic in the fascial plane below the erector spinae muscle group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Ultrasound-guided QL block has been reported to provide effective analgesia in patients undergoing lower abdominal surgical procedures, including in patients undergoing abdominal hysterectomy. Ultrasound guidance offers a number of advantages, including the ability to visualize the anatomy, perform real-time navigation, and direct observation of local anesthetic spread. The QL block is performed via ultrasound-guided injection of local anesthetic in the fascial planes above or below the QL muscle
Study: NCT05600829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BWLT+CR
Description: Patients will attend twelve 2-hour group-based weekly sessions (over Zoom) in addition to their twice-weekly CR exercise sessions, followed by biweekly follow-up sessions alternating between individual phone-based sessions with a facilitator, and group-based sessions for an additional 12 weeks. The empirically validated ASPIRE BWLT was recently adapted for an AF population with obesity. Briefly, the BWLT was modified to incorporate education and practical strategies requested by patients, including AF risk factor management, pathophysiology, medications, and disease course; exercising with AF; and coping with difficult emotions regarding AF. Weekly treatment goals focus on nutrition and moderate calorie reduction while emphasizing adherence to an individualized CR exercise prescription. The BWLT program will be delivered by senior clinical psychology PhD students and supervised by a registered Clinical Health Psychologist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CR-Only
Description: The CR program consists of education, medication management, risk factor modification and 12 weeks of twice-weekly supervised cardiovascular exercise sessions. Patients with AF undergo a symptom-limited graded exercise stress test at intake, 12-weeks, 24-weeks, and 1-year post-randomization, where cardiorespiratory fitness (i.e., peak metabolic equivalents \[METS\]) and cardiometabolic risk factors (blood pressure, blood lipid profile, BMI, waist circumference, depression and anxiety symptoms, tobacco use, and exercise volume) are assessed.
Study: NCT06209294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104(10 mg/kg) d1,22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=2 d1,8,15,22, 29, 36

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125mg／m2 d1,8,15,22,29,36
Study: NCT06172816

Intervention type: OTHER
Intervention: SARS-CoV-2
Description: a virus infection

Intervention type: OTHER
Intervention: SARS-CoV-2
Description: a virus infection
Study: NCT05325229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for injection (Albumin-bound)
Description: Docetaxel for injection (Albumin-bound), by intravenous infusion，75 mg/m\^2 or 100 mg/m\^2 once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab, by intravenous infusion, 15 mg/kg once every 3 weeks.
Study: NCT04680624

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fecal sample collection
Description: During the study, patients will be ask to collect fecal samples using sample collection kits. A total of 4 stool samples per patient will be collected.
Study: NCT04603469

Intervention type: OTHER
Intervention: Non invasive blood pressure
Description: measurement of blood pressure during induction of general anesthesia
Study: NCT05077618

Intervention type: OTHER
Intervention: sampling of dental plaque and blood sample during the treatment
Description: sampling of dental plaque and blood sample analysed on day 1
Study: NCT05351424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual Intervention- Radiation Therapy Education
Description: A video with educational information will be shown regarding radiation therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure
Description: Brochure with written information will be given to the subject regarding radiation therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual Intervention- Cancer Clinical Trials Education
Description: A video with educational information will be shown regarding cancer clinical trials.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCI Taking Part in Cancer Research Studies Brochure
Description: Brochure with written information will be given to the subject regarding cancer clinical trials.
Study: NCT04056624

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High carotenoid juice
Description: Juice with high carotenoids

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High carotenoid juice
Description: Juice with high carotenoids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control - Apple juice
Description: Juice with negligible carotenoids
Study: NCT04771780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: oral administration
Study: NCT06000436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.
Study: NCT05441540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal Jugular Vein Compression Collar
Description: The current FDA approved internal jugular vein compression collar, marketed as the Q collar, is manufactured by Q30 Innovations Home. It is designed to be worn around the neck of individuals aged 13 and older. It functions by lightly compressing the internal jugular vein's bilaterally, safely increasing intracranial volume and intracranial pressure. The FDA approved neck collar device is made of a thermoplastic elastomer that is specifically fitted to an individual to provide mild internal jugular vein compression. The product was developed and confirmed with ultrasonography to confirm appropriate fit and compression of the vein based on an athlete's neck circumference.
Study: NCT05399108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Lateral Approach Catheterization of Jugular Internal Vein
Description: The jugular internal vein is displayed on its short axis. On the image are displayed the trapezius muscle and layers of skin. Just above the trapezius muscle using the in-plane technique is done puncture of the vein. By Seldinger's technique, catheterization is done. The whole procedure is done according to the newest international recommendations for central vein catheterization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Conventional Approach Catheterization of Jugular Internal Vein
Description: The jugular internal vein is displayed on its short axis. The cannulation is done by the conventional approach (middle approach - the most frequently used).
Study: NCT06168825

Intervention type: OTHER
Intervention: Mind Over Matter (MOM)
Description: Each participant's involvement in the study will include:~* Attending a Pre-Program Orientation which will be held a week before the first MOM Session.~* Completing 5 weekly sessions of MOM~* Completing 2 surveys; one will be given before the start of the intervention (a pre-test) and the other will be given after the last MOM Session (a post-test)~Participants will also have the option to participate in an optional Focus Group session which will occur a week after the last MOM Session ends~Participants will spend about 6 weeks in this study. If they decide to participate in the optional session, they will spend about 7 weeks in this study.~Please note, this entire Intervention will be offered online. There will be no in-person sessions or visits.
Study: NCT05953974

Intervention type: OTHER
Intervention: Clinical score of Granillo and al.
Description: Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
Study: NCT05016804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05666440

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.
Description: A superior limbal-based conjunctival flap and a paracentesis. A superficial rectangular scleral flap 4×4 mm was fashioned and dissected forward toward the limbus. A deep sceral flap (2×2 mm) was then created toward the limbus underneath the superficial flap exposing the scleral spur and deroofing SC. Viscoelastic (Healon GV, Pfizer, NY) was injected (using a standard 30 G viscocanalostomy cannula) into the ostia of SC Then, the 5/0 polypropylene suture tip was cauterized into a blunt tip (to ensure atraumatic probing of SC). The tip was inserted into the left ostium of SC using a microsurgical forceps and advanced through the whole circumference of the canal. When the tip presented to the right ostium the AC was filled with a viscoelastic through the paracentesis and traction was applied to approximate both ends of the 5/0 polypropylene suture, thus creating a visco-360-degree trabeculotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.
Description: A fornixbased conjunctival incision followed by creation of a partial thickness (about 50% thickness) triangular (4×4×4 mm) scleral fap, followed by localization of Schlemm's canal by radial incisions straddling the limbus. High viscosity sodium hyaluronate (Healon GV, Pfzer) was then slowly injected into both ends of Schlemm's canal. Trabeculotomy was completed using the standard Harm's trabeculotome (Geuder Instruments), the scleral fap was then secured tightly with interrupted 10/0 Nylon sutures and conjunctival closure ensued.
Study: NCT05953974

Intervention type: OTHER
Intervention: Clinical score of Granillo and al.
Description: Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.

Intervention type: OTHER
Intervention: Clinical score of Granillo and al.
Description: Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.

Intervention type: OTHER
Intervention: Clinical score of Granillo and al.
Description: Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
Study: NCT06140043

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient consultation
Description: Providing information about the current clinical problem of orthognatic surgery patients and the proposed treatment for it.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient consultation
Description: Providing information about the current clinical problem of orthognatic surgery patients and the proposed treatment for it.
Study: NCT00818246

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LumiPhase-R™, OPUSMED Inc. Montreal, Canada
Description: 660 nm wavelength delivered in a sequential pulsing mode
Study: NCT04762836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Antibiotic medication that augments the function of NMDA-receptors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioning
Description: During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conditioning
Description: During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction
Description: During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Extinction
Description: During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fMRI
Description: In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control in oral form
Study: NCT06235918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 260mg/m\^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles
Study: NCT05797363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous midwife support
Description: The individuals included in the experimental group will be provided with consultancy services on many issues from the pre-pregnancy period to the postpartum period.
Study: NCT04767672

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non digestible carbohydrates
Description: the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
Study: NCT06185894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterovesical tourniquet before uterine devascularization steps
Description: Insertion of a Foley catheter tourniquet through broad ligament apertures \& tightening it immediately before hysterotomy in cases of conservative management of placenta accreta spectrum

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional conservative surgery
Description: Conventional conservative surgery
Study: NCT06195293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Polypeptide Vaccine
Description: Deliver neoantigen polypeptide vaccine into patients for anti-ancer therapy.
Study: NCT04711499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue
Description: The intervention will be assessing the participant in a fatigued state compared to a non fatigued state

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue
Description: The intervention will be assessing the participant in a fatigued state compared to a non fatigued state
Study: NCT06422429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Traditional deep-fried Youtiao
Description: 45g 4 times a week for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI Youtiao
Description: 45g 4 times a week for 4 months
Study: NCT05400187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body composition assessment and smart-phone based counselling
Description: As for the body composition assessment, body fat and muscle thickness, body fat percentage and distribution will be measured and a brief face-to-face counseling soon after the measurement will be implemented to the participants. Body assessment were measured by the InBody 270 (Biospace, Seoul, Korea) device, which provides a convenient way of accurate body fat measurement comparable with those obtained using air displacement plethysmography (ADP) (about 90% precision).~As for the Whatsapp-based counselling and communication session, qualitative dietary counselling will be offered every two weeks through the Whatsapp. One session contains 15 minutes, including the topics like making a balanced diet (55 % glucose, 30 % lipids and 15 % proteins), diversifying food intake, dietary advices and recommendations in healthy eating behaviors (e.g., eat slowly, eat at a regular time, avoid to skip a meal, drink at least 1.5 L of water each day).
Study: NCT04705337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
Study: NCT06495216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation by a Balloon Catheter with the TRUPULSE Generator
Description: Pulsed field ablation balloon catheter and TRUPULSE generator will be used for PV ablation.
Study: NCT05167721

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Mesenchymal Stem Cells
Description: Autologous Mesenchymal Stem Cells administered intrathecally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Mesenchymal Stem Cells
Description: Autologous Mesenchymal Stem Cells administered intrathecally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo administered intrathecally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intrathecally
Study: NCT06342648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Water Injection
Description: Injection of intracutaneous sterile water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium injection
Description: Injection of intramuscular diclofenac sodium
Study: NCT06366334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: See arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: See arm description
Study: NCT05982834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin combined with fruquintinib and Tislelizumab
Description: Disitamab Vedotin 2.5mg/m2 ivgtt d1,15, fruquintinib 4mg qd po d1-21 and Tislelizumab 300mg ivgtt,q4w
Study: NCT05082402

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Swept Source Optical Coherence Tomography Angiography
Description: The PLEX Elite 9000 is an FDA cleared research device for use in ocular imaging obtained by Northwestern University by way of a purchase agreement with the manufacturer, Carl Zeiss Meditec, Inc. It is currently unavailable outside of participation in the ARI Network, a cloudbased storage and image processing platform using deidentified information shared between academic institutions. The ARI Network is managed by a group of physicians and scientists from around the world that are working to better understand eye diseases.
Study: NCT04942119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Description: 1. Correction of magnesium and/or potassium deficit and the underlying disease.~2. Education reinforcing optimal diet and exercise, in addition to, post-nutrition assessment , diabetes self-care activities and adherence will be given at each follow up visit by a specialized dietitian.~3. Comprehensive medication therapy management by clinical pharmacist, and medication adherence will be measured by adherence questionnaire as well as fixed medication possession ratio (FMPR).
Study: NCT05178693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Cedazuridine 100mg + 35mg decitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: Peptide receptor radionuclide therapy (PRRT)
Study: NCT01600001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05306548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical carpal tunnel release
Description: Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical carpal tunnel release
Description: Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection, Triamcinolone Hexacetonide, Per 5 Mg
Description: Ultrasound-guided injection of 20 mg of triamcinolone hexacetonide (or -acetonide) into the carpal tunnel space close to the median nerve
Study: NCT04698655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information on treatment options
Description: Asked to read two A4 pages of information on treatment options (osteoarthritis treatment options)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information on treatment options
Description: Asked to read two A4 pages of information on treatment options (osteoarthritis treatment options)
Study: NCT04740333

Intervention type: OTHER
Intervention: No intervention- observational study
Description: No intervention- observational study

Intervention type: OTHER
Intervention: No intervention- observational study
Description: No intervention- observational study
Study: NCT06305026

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle- and skin biopsies
Description: RA patients with and without concomitant fibromyalgia will be examined with muscle and skin biopsies.